Education
About Us
Working with TipRanks
Follow Us
Novartis AG (DE:NOT)
XETRA:NOT
NOT Stock Chart & Stats
Day’s Range― - ―
52-Week Range€79.74 - €111.38
Previous CloseN/A
Volume24.84K
Average Volume (3M)1.61K
Market Cap
CHF198.84B
Enterprise Value€208.96B
Total Cash (Recent Filing)CHF7.00B
Total Debt (Recent Filing)CHF32.64B
Price to Earnings (P/E)16.5
Beta0.21
Next Earnings
Oct 28, 2025EPS Estimate
1.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.06
Shares Outstanding2,112,421,900
10 Day Avg. Volume1,244
30 Day Avg. Volume1,615
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF108.46Price Target Upside4.31% Upside
Rating ConsensusHold
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNovartis announced positive topline data for ianalumab in both NEPTUNUS 1 and 2 trials in Sjogren’s syndrome, an autoimmune disease with a significant patient population and unmet need given the lack of any approved treatment options.
Product PotentialThere is potential for an upgrade cycle driven mainly by Kisqali, Scemblix, and Pluvicto.
Stock PerformanceNovartis has been the best performer on a 1, 3 and 5 year basis among the 'Value Stocks/Innovation Laggards'.
Bears Say
Growth OutlookAs generic competition impact steps up in the coming years, Novartis' growth rate is expected to structurally reset lower.
Patent ExpiryThere is more to be done in the face of $32bn in sales which faces generic competition out to 2030.
Valuation ConcernsThe recommendation remains Neutral due to valuation concerns and slowing growth.
Novartis AG News
NOT FAQ
What was Novartis AG’s price range in the past 12 months?
Novartis AG lowest stock price was €79.74 and its highest was €111.38 in the past 12 months.
What is Novartis AG’s market cap?
Novartis AG’s market cap is CHF198.84B.
When is Novartis AG’s upcoming earnings report date?
Novartis AG’s upcoming earnings report date is Oct 28, 2025 which is in 41 days.
How were Novartis AG’s earnings last quarter?
Novartis AG released its earnings results on Jul 17, 2025. The company reported €2.064 earnings per share for the quarter, beating the consensus estimate of €2.005 by €0.059.
Is Novartis AG overvalued?
According to Wall Street analysts Novartis AG’s price is currently Undervalued.
Does Novartis AG pay dividends?
Novartis AG does not currently pay dividends.
What is Novartis AG’s EPS estimate?
Novartis AG’s EPS estimate is 1.92.
How many shares outstanding does Novartis AG have?
Novartis AG has 2,112,421,900 shares outstanding.
What happened to Novartis AG’s price movement after its last earnings report?
Novartis AG reported an EPS of €2.064 in its last earnings report, beating expectations of €2.005. Following the earnings report the stock price went down -1.686%.
Which hedge fund is a major shareholder of Novartis AG?
Currently, no hedge funds are holding shares in DE:NOT
Company Description
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
NOT Stock 12 Month Forecast
Average Price Target
€108.46
▲(4.31% Upside)
Technical Analysis
Options Prices
Currently, No data available
---